biologics
| 1 min read
The expanded partnership reflects strong demand for Lonza’s global biologics outsourcing platform, spanning diversified clinical and commercial manufacturing programs.
| 2 min read
A €45m expansion enables a seamless, single-site pathway from early protein discovery through CMC development to Phase 1/2 GMP manufacturing for complex biologics.
| 4 min read
New instrument launches from two major vendors at this year's conference reflected shared priorities: higher proteome coverage, richer characterization of complex biotherapeutics, and tighter integration of AI.
| 5 min read
Disruptions to key Middle East logistics corridors are rippling through pharmaceutical supply chains, raising costs and testing resilience, but not yet triggering shortages.
| 3 min read
As therapies grow more complex, inactive ingredient innovation is needed to improve drug impact and access.
| 2 min read
The initiative aims to identify and support new ideas for innovative oral formulations for peptide drugs such as GLP-1 receptor agonists via BioMed X’s global talent sourcing and incubation model.
| 2 min read
New data suggests icotrokinra could challenge injectables with once-daily targeted peptide.
| 2 min read
Bio-Rad has expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies and SpyCatcher reagents, enhancing support for bioanalytical assay development and antibody drug research.
| 5 min read
Advances in microfluidics are enabling more powerful, high throughput applications in single cell and therapeutic discovery.
| 5 min read
Biologics like monoclonal antibodies and mRNA vaccines are complex drugs. Yongchao Su uses biophysical tools and innovative strategies to understand them better.
